VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate

Journal of Lipid Research

Volumn 49, Issue 12, 2008, Pages 2641-2647

  Farnier, Michel ^a   Perevozskaya, Inna ^b   Taggart, William V ^b   Kush, Debra ^b   Mitchel, Yale B ^b  

^a Point Medical   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Atherogenic; Cholesterol absorption inhibition; Fibrates; Lipids; Statin; Vertical Auto Profile II

Indexed keywords

APOLIPOPROTEIN B; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTILIPEMIC AGENT; AZETIDINE DERIVATIVE; EZETIMIBE; LIPOPROTEIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GEL ELECTROPHORESIS; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; CLASSIFICATION; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTILIPEMIC AGENTS; AZETIDINES; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; MIDDLE AGED; PROCETOFEN; SIMVASTATIN;

EID: 59649105853     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P800034-JLR200     Document Type: Article

References (22)

1. Krauss, R. M., F. T. Lindgren, P. T. Williams, S. F. Kelsey, J. Brensike, K. Vranizan, K. M. Detre, and R. I. Levy. 1987. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet. 2: 62-66.
2. Austin, M. A., J. L. Breslow, C. H. Hennekens, J. E. Buring, W. C. Willett, and R. M. Krauss. 1988. Low-density lipoprotein subclass patterns and risk of myocardial infarction. J. Am. Med. Assoc. 260: 1917-1921.
3. Stampfer, M. J., R. M. Krauss, J. Ma, P. J. Blanche, L. G. Holl, F. M. Sacks, and C. H. Hennekens. 1996. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. J. Am. Med. Assoc. 276: 882-888.
4. Gardner, C. D., S. P. Fortmann, and R. M. Krauss. 1996. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. J. Am. Med. Assoc. 276: 875-881.
5. Mack, W. J., R. M. Krauss, and H. N. Hodis. 1996. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler. Thromb. Vasc. Biol. 16: 697-704.
6. Sacks, F. M., P. Alaupovic, L. A. Moye, T. G. Cole, B. Sussex, M. J. Stampfer, M. A. Pfeffer, and E. Braunwald. 2000. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 102: 1886-1892.
7. Ballantyne, C. M., A. G. Olsson, T. J. Cook, M. F. Mercuri, T. R. Pedersen, and J. Kjekshus. 2001. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 104: 3046-3051.
8. The BIP Study Group. 2000. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 102: 21-27.
9. Frick, M. H., O. Elo, K. Haapa, O. P. Heinonen, P. Heinsalmi, P. Helo, J. K. Huttunen, P. Kaitaniemi, P. Koskinen, and V. Manninen. 1987. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317: 1237-1245.
10. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. 2001. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J. Am. Med. Assoc. 285: 2486-2497.
11. Elisaf, M. 2002. Effects of fibrates on serum metabolic parameters. Curr. Med. Res. Opin. 18: 269-276.
12. 2006. TRICOR (fenofibrate tablets). North Chicago, IL. Abbott. PDR Electronic Library. Accessed October 2, 2008 at http://www.thomsonhc.com/pdrel/librarian.
13. Fazio, S., and M. F. Linton. 2004. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr. Atheroscler. Rep. 6: 148-157.
14. Grundy, S. M., G. L. Vega, Z. Yuan, W. P. Battisti, W. E. Brady, and J. Palmisano. 2005. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The SAFARI Trial). Am. J. Cardiol. 95: 462-468.
15. Farnier, M., M. Freeman, G. Macdonell, I. Perevozskaya, M. Davies, Y. Mitchel, and B. Gumbiner. 2005. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J. 26: 897-905.
16. Farnier, M., E. Roth, B. Gil-Extremera, G. F. Mendez, G. Macdonell, C. Hamlin, I. Perevozskaya, M. J. Davies, D. Kush, and Y. B. Mitchel. Ezetimibe/Simvastatin 1 Fenofibrate Study Group. 2007. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am. Heart J. 153: 335e1-335e8.
17. Kulkarni, K. R., S. M. Marcovina, R. M. Krauss, D. W. Garber, A. M. Glasscock, and J. P. Segrest. 1997. Quantification of HDL2 and HDL3 cholesterol by the Vertical Auto Profile-II (VAP-II) methodology. J. Lipid Res. 38: 2353-2364.
18. Kulkarni, K. R., D. W. Garber, M. K. Jones, and J. P. Segrest. 1995. Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology. J. Lipid Res. 36: 2291-2302.
19. Kulkarni, K. R., D. W. Garber, S. M. Marcovina, and J. P. Segrest. 1994. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J. Lipid Res. 35: 159-168.
20. Goff, D. C., Jr., R. B. D'Agostino, Jr., S. M. Haffner, and J. D. Otvos. 2005. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism. 54: 264-270.
21. Tatami, R., H. Mabuchi, K. Ueda, R. Ueda, T. Haba, T. Kametani, S. Ito, J. Koizumi, M. Ohta, S. Miyamoto, et al. 1981. Intermediatedensity lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation. 64: 1174-1184.
22. Ballantyne, F. C., R. S. Clark, H. S. Simpson, and D. Ballantyne. 1982. High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects. Metabolism. 31: 433-437.